Salarius Pharmaceuticals Alpha and Beta Analysis

SLRXDelisted Stock  USD 0.82  0.05  6.49%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Salarius Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Salarius Pharmaceuticals over a specified time horizon. Remember, high Salarius Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Salarius Pharmaceuticals' market risk premium analysis include:
Beta
0.64
Alpha
(1.97)
Risk
8.44
Sharpe Ratio
0.0508
Expected Return
0.43
Please note that although Salarius Pharmaceuticals alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Salarius Pharmaceuticals did 1.97  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Salarius Pharmaceuticals stock's relative risk over its benchmark. Salarius Pharmaceuticals has a beta of 0.64  . As returns on the market increase, Salarius Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Salarius Pharmaceuticals is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Salarius Pharmaceuticals Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Salarius Pharmaceuticals market risk premium is the additional return an investor will receive from holding Salarius Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Salarius Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Salarius Pharmaceuticals' performance over market.
α-1.97   β0.64

Salarius Pharmaceuticals Fundamentals Vs Peers

Comparing Salarius Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Salarius Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Salarius Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Salarius Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Salarius Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Salarius Pharmaceuticals to competition
FundamentalsSalarius PharmaceuticalsPeer Average
Return On Equity-1.4-0.31
Return On Asset-0.7-0.14
Current Valuation2.12 M16.62 B
Shares Outstanding5.86 M571.82 M
Shares Owned By Insiders0.63 %10.09 %
Shares Owned By Institutions5.21 %39.21 %
Number Of Shares Shorted184.64 K4.71 M

Salarius Pharmaceuticals Opportunities

Salarius Pharmaceuticals Return and Market Media

The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Salarius Pharmaceuticals Announces Pricing of 7 Million Underwritten Public Offering
11/11/2025
2
Strong Earnings and Biotech Resilience Define the Midweek Momentum
11/12/2025
3
Salarius Pharmaceuticals Cites Errors on SP CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Ma...
11/19/2025
4
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
12/01/2025
5
Comparing NRx Pharmaceuticals and Salarius Pharmaceuticals
12/16/2025
6
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
12/24/2025

About Salarius Pharmaceuticals Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Salarius or other delisted stocks. Alpha measures the amount that position in Salarius Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Salarius Pharmaceuticals Upcoming Company Events

As portrayed in its financial statements, the presentation of Salarius Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Salarius Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Salarius Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Salarius Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Salarius Pharmaceuticals' management manipulating its earnings.
25th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Salarius Pharmaceuticals

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Consideration for investing in Salarius Stock

If you are still planning to invest in Salarius Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Salarius Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal